154 related articles for article (PubMed ID: 23945309)
1. HCV infected prisoners: should they be still considered a difficult to treat population?
Iacomi F; Iannicelli G; Franceschini A; Migliorisi P; Rosati S; Piselli P; Scognamiglio P; De Carli G; Marcellini S; Palmieri F
BMC Infect Dis; 2013 Aug; 13():374. PubMed ID: 23945309
[TBL] [Abstract][Full Text] [Related]
2. Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.
Marco A; Antón JJ; Trujols J; Saíz de la Hoya P; de Juan J; Faraco I; Caylà JA;
BMC Infect Dis; 2015 Aug; 15():355. PubMed ID: 26286450
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
[TBL] [Abstract][Full Text] [Related]
4. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the hepatitis C testing, care and treatment program in the country of Georgia's corrections system, December 2013 - April 2015.
Harris AM; Chokoshvili O; Biddle J; Turashvili K; Japaridze M; Burjanadze I; Tsertsvadze T; Sharvadze L; Karchava M; Talakvadze A; Chakhnashvili K; Demurishvili T; Sabelashvili P; Foster M; Hagan L; Butsashvili M; Morgan J; Averhoff F
BMC Public Health; 2019 May; 19(Suppl 3):466. PubMed ID: 32326938
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates.
Marco A; Roget M; Cervantes M; Forné M; Planella R; Miquel M; Ortiz J; Navarro M; Gallego C; Vergara M;
J Viral Hepat; 2018 Nov; 25(11):1280-1286. PubMed ID: 29851225
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hepatitis C virus treatment between incarcerated and community patients.
Rice JP; Burnett D; Tsotsis H; Lindstrom MJ; Cornett DD; Voermans P; Sawyer J; Striker R; Lucey MR
Hepatology; 2012 Oct; 56(4):1252-60. PubMed ID: 22505121
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis C in Canadian prison inmates.
Farley JD; Wong VK; Chung HV; Lim E; Walters G; Farley TA; Yoshida EM
Can J Gastroenterol; 2005 Mar; 19(3):153-6. PubMed ID: 15776135
[TBL] [Abstract][Full Text] [Related]
10. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
11. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.
Sterling RK; Brown RS; Hofmann CM; Luketic VA; Stravitz RT; Sanyal AJ; Contos MJ; Mills AS; Smith V; Shiffman ML
Am J Gastroenterol; 2005 Feb; 100(2):313-21. PubMed ID: 15667488
[TBL] [Abstract][Full Text] [Related]
12. ANTIVIRAL TREATMENT OF HEPATITIS C IN SERBIAN PRISON SETTING: MEDICAL TREATMENT OUTCOMES AND PATIENTS' ADHERENCE.
Simonović Babić J; Bojović K; Delić D; Katanić N; Mitrović N; Malinić J
Med Pregl; 2016; 69(3-4):85-91. PubMed ID: 27506095
[TBL] [Abstract][Full Text] [Related]
13. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
[TBL] [Abstract][Full Text] [Related]
16. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
17. A golden opportunity: the treatment of hepatitis C in HIV-infected inmates.
McGovern B
J Addict Dis; 2008; 27(2):69-73. PubMed ID: 18681193
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
Marco A; Esteban JI; Solé C; da Silva A; Ortiz J; Roget M; Sarriera C; Teixidó N; Guerrero RA; Caylà JA
J Hepatol; 2013 Jul; 59(1):45-51. PubMed ID: 23523577
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
Bate JP; Colman AJ; Frost PJ; Shaw DR; Harley HA
J Gastroenterol Hepatol; 2010 Jul; 25(7):1276-80. PubMed ID: 20594255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
